IRLAB provides additional efficacy data from the Phase IIb study of pirepemat in patients with Parkinson’s disease

Gothenburg, Sweden, March 28, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson’s disease, today announces further results based on prespecified in-depth efficacy analyses of the data generated in the Phase IIb dose finding and efficacy study of pirepemat (REACT-PD). The analysis reveals that in a medium plasma concentration range, pirepemat reduced the fall rate by as much as 51.5% after three months of treatment. This effect is highly clinically meaningful and statistically significant (p<0.05 vs. placebo). Based on these compelling results, the company now continues with further analyses of the study data to reach a decision on how to best design forthcoming studies during the continued clinical development of the drug candidate.

IRLAB to initiate a study of IRL757 in Parkinsons’s disease with full financial backing from its development partner MSRD

IRLAB publishes preclinical data on mesdopetam in the esteemed European Journal of Neuroscience